425: Penumbra Stockholders Approve Merger with Boston Scientific

Penumbra, Inc. announced that its stockholders overwhelmingly approved the merger agreement with Boston Scientific Corporation at a special meeting held on May 6, 2026.

Summary

• Penumbra, Inc. held a special meeting of stockholders on May 6, 2026, to vote on several proposals.
• The primary proposal, to adopt the Agreement and Plan of Merger with Boston Scientific Corporation, was approved by a significant majority of votes.
• Stockholders also approved, on an advisory basis, the compensation for named executive officers related to the merger.
• An adjournment proposal was also presented but was deemed unnecessary as the merger proposal passed.
• The approval of the merger proposal is a key condition for the consummation of the merger, which remains subject to other closing conditions, including antitrust reviews.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, indicating strong shareholder support for the acquisition by Boston Scientific, although finalization depends on regulatory approvals.

Positives

• The merger agreement with Boston Scientific Corporation was overwhelmingly approved by Penumbra's stockholders, with 28,564,786 votes in favor.
• The advisory compensation proposal related to the merger also received strong support, with 27,811,605 votes in favor.
• A quorum was established with 28,665,933 shares present in person or by proxy, indicating significant stockholder engagement.

Risks

• Consummation of the merger is still subject to the satisfaction or waiver of other closing conditions.
• These conditions include the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• Additional antitrust, competition, or foreign investment law clearances or approvals from non-U.S. jurisdictions are also required.

Future Outlook

The consummation of the merger remains subject to the satisfaction or waiver of other closing conditions, including antitrust reviews in the U.S. and certain non-U.S. jurisdictions.

Industry Context

StockSavvy.ai notes that the overwhelming approval of this merger by Penumbra's stockholders is a positive signal for the transaction's completion, though finalization hinges on regulatory approvals, a common hurdle in significant healthcare technology acquisitions.

Stakeholder Impact

• Shareholders: The approval of the merger by stockholders is a critical step towards the completion of the acquisition, which will result in shareholders receiving consideration for their shares.
• Employees: The merger's completion may lead to integration of Penumbra's operations into Boston Scientific, potentially impacting employee roles and structures.
• Creditors: The financial stability and credit standing of the combined entity will be influenced by the merger.
• Customers: The integration of products and services may affect customer offerings and support.

Next Steps

• Satisfy or waive remaining closing conditions in the Merger Agreement.
• Obtain expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• Receive clearances or approvals (or expiration/termination of waiting periods) under antitrust, competition, or foreign investment laws of certain non-U.S. jurisdictions.

Key Dates

Recommendation

The filing confirms stockholder approval for the merger with Boston Scientific, which is a significant positive step. However, the completion is still contingent on regulatory approvals. Investors should hold their positions pending the finalization of the deal and further clarity on integration post-merger.

Keywords

merger, acquisition, Boston Scientific, Penumbra, stockholder vote, antitrust, regulatory approval, special meeting